Colon Cancer - Pipeline Review, H2 2016

Date: December 30, 2016
Pages: 722
Price:
US$ 2,500.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C10829AE6C0EN
Leaflet:

Download PDF Leaflet

Colon Cancer - Pipeline Review, H2 2016
Colon Cancer - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colon Cancer – Pipeline Review, H2 2016, provides an overview of the Colon Cancer (Oncology) pipeline landscape.

Colon cancer is cancer that starts in the large intestine (colon). There is no single cause of colon cancer. Nearly all colon cancers begin as noncancerous (benign) polyps, which slowly develop into cancer. Many cases of colon cancer have no symptoms. The following symptoms may indicate colon cancer abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, or other change in bowel habits, narrow stools and weight loss with no known reason. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Colon Cancer – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Colon Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Colon Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Colon Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 6, 35, 3, 155 and 14 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 2, 46 and 16 molecules, respectively.

Colon Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Colon Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Colon Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Colon Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Colon Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Colon Cancer (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Colon Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Colon Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Colon Cancer Overview
Therapeutics Development
Colon Cancer - Therapeutics under Development by Companies
Colon Cancer - Therapeutics under Investigation by Universities/Institutes
Colon Cancer - Pipeline Products Glance
Colon Cancer - Products under Development by Companies
Colon Cancer - Products under Investigation by Universities/Institutes
Colon Cancer - Companies Involved in Therapeutics Development
Colon Cancer - Therapeutics Assessment
Drug Profiles
Colon Cancer - Dormant Projects
Colon Cancer - Discontinued Products
Colon Cancer - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Colon Cancer, H2 2016
Number of Products under Development for Colon Cancer - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Development by Companies, H2 2016 (Contd..3)
Number of Products under Development by Companies, H2 2016 (Contd..4)
Number of Products under Development by Companies, H2 2016 (Contd..5)
Number of Products under Development by Companies, H2 2016 (Contd..6)
Number of Products under Development by Companies, H2 2016 (Contd..7)
Number of Products under Development by Companies, H2 2016 (Contd..8)
Number of Products under Development by Companies, H2 2016 (Contd..9)
Number of Products under Development by Companies, H2 2016 (Contd..10)
Number of Products under Investigation by Universities/Institutes, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Development by Companies, H2 2016 (Contd..4)
Products under Development by Companies, H2 2016 (Contd..5)
Products under Development by Companies, H2 2016 (Contd..6)
Products under Development by Companies, H2 2016 (Contd..7)
Products under Development by Companies, H2 2016 (Contd..8)
Products under Development by Companies, H2 2016 (Contd..9)
Products under Development by Companies, H2 2016 (Contd..10)
Products under Development by Companies, H2 2016 (Contd..11)
Products under Development by Companies, H2 2016 (Contd..12)
Products under Investigation by Universities/Institutes, H2 2016
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2016 (Contd..3)
Colon Cancer - Pipeline by Actinium Pharmaceuticals Inc, H2 2016
Colon Cancer - Pipeline by Adamed Sp z oo, H2 2016
Colon Cancer - Pipeline by Adgero Biopharmaceuticals Inc, H2 2016
Colon Cancer - Pipeline by Advanced Cancer Therapeutics, H2 2016
Colon Cancer - Pipeline by Advanced Proteome Therapeutics Corp, H2 2016
Colon Cancer - Pipeline by Advenchen Laboratories LLC, H2 2016
Colon Cancer - Pipeline by Aeglea BioTherapeutics Inc, H2 2016
Colon Cancer - Pipeline by Affimed GmbH, H2 2016
Colon Cancer - Pipeline by Agenus Inc, H2 2016
Colon Cancer - Pipeline by AGV Discovery SAS, H2 2016
Colon Cancer - Pipeline by AIMM Therapeutics BV, H2 2016
Colon Cancer - Pipeline by Almac Discovery Ltd, H2 2016
Colon Cancer - Pipeline by Ambrx Inc, H2 2016
Colon Cancer - Pipeline by Anavex Life Sciences Corp, H2 2016
Colon Cancer - Pipeline by AndroScience Corp, H2 2016
Colon Cancer - Pipeline by Aphios Corp, H2 2016
Colon Cancer - Pipeline by Aposense Ltd, H2 2016
Colon Cancer - Pipeline by Aptose Biosciences Inc, H2 2016
Colon Cancer - Pipeline by AstraZeneca Plc, H2 2016
Colon Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H2 2016
Colon Cancer - Pipeline by BCN Biosciences LLC, H2 2016
Colon Cancer - Pipeline by Bio-Path Holdings Inc, H2 2016
Colon Cancer - Pipeline by BioCancell Ltd, H2 2016
Colon Cancer - Pipeline by Biogazelle NV, H2 2016
Colon Cancer - Pipeline by Bioncotech Therapeutics SL, H2 2016
Colon Cancer - Pipeline by Blirt SA, H2 2016
Colon Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016
Colon Cancer - Pipeline by Can-Fite BioPharma Ltd, H2 2016
Colon Cancer - Pipeline by Celprogen Inc, H2 2016
Colon Cancer - Pipeline by Chiome Bioscience Inc, H2 2016
Colon Cancer - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2016
Colon Cancer - Pipeline by CytomX Therapeutics Inc, H2 2016
Colon Cancer - Pipeline by Cytune Pharma SAS, H2 2016
Colon Cancer - Pipeline by CZ BioMed Corp, H2 2016
Colon Cancer - Pipeline by Daiichi Sankyo Company Ltd, H2 2016
Colon Cancer - Pipeline by DEKK-TEC Inc, H2 2016
Colon Cancer - Pipeline by Eli Lilly and Company, H2 2016
Colon Cancer - Pipeline by EntreChem SL, H2 2016
Colon Cancer - Pipeline by EnzymeBioSystems, H2 2016
Colon Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016
Colon Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016
Colon Cancer - Pipeline by GlycaNova Norway AS, H2 2016
Colon Cancer - Pipeline by GlycoMimetics Inc, H2 2016
Colon Cancer - Pipeline by Grunenthal GmbH, H2 2016
Colon Cancer - Pipeline by Halozyme Therapeutics Inc, H2 2016
Colon Cancer - Pipeline by Hamlet Pharma AB, H2 2016
Colon Cancer - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2016
Colon Cancer - Pipeline by Helix BioPharma Corp, H2 2016
Colon Cancer - Pipeline by Histogen Inc, H2 2016
Colon Cancer - Pipeline by Horizon Pharma Plc, H2 2016
Colon Cancer - Pipeline by Idera Pharmaceuticals Inc, H2 2016
Colon Cancer - Pipeline by Immune Pharmaceuticals Inc, H2 2016
Colon Cancer - Pipeline by Immunome Inc, H2 2016
Colon Cancer - Pipeline by Immunomedics Inc, H2 2016
Colon Cancer - Pipeline by Immunotope Inc, H2 2016
Colon Cancer - Pipeline by Immupharma Plc, H2 2016
Colon Cancer - Pipeline by IMPACT Therapeutics Inc, H2 2016
Colon Cancer - Pipeline by Incuron LLC, H2 2016
Colon Cancer - Pipeline by Infinity Pharmaceuticals Inc, H2 2016
Colon Cancer - Pipeline by Inflection Biosciences Ltd, H2 2016
Colon Cancer - Pipeline by Innopharmax Inc, H2 2016
Colon Cancer - Pipeline by Intezyne Technologies Inc, H2 2016
Colon Cancer - Pipeline by Ironwood Pharmaceuticals Inc, H2 2016
Colon Cancer - Pipeline by Jasco Pharmaceuticals LLC, H2 2016
Colon Cancer - Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H2 2016
Colon Cancer - Pipeline by JW Pharmaceutical Corp, H2 2016
Colon Cancer - Pipeline by Karyopharm Therapeutics Inc, H2 2016
Colon Cancer - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2016
Colon Cancer - Pipeline by Les Laboratoires Servier SAS, H2 2016
Colon Cancer - Pipeline by Lipocure Ltd, H2 2016
Colon Cancer - Pipeline by Lupin Ltd, H2 2016
Colon Cancer - Pipeline by Lymphocyte Activation Technologies SA, H2 2016
Colon Cancer - Pipeline by MabVax Therapeutics Holdings Inc, H2 2016
Colon Cancer - Pipeline by MacroGenics Inc, H2 2016
Colon Cancer - Pipeline by MaxiVAX SA, H2 2016
Colon Cancer - Pipeline by Meabco A/S, H2 2016
Colon Cancer - Pipeline by Medicenna Therapeutics Inc, H2 2016
Colon Cancer - Pipeline by Microlin Bio, Inc., H2 2016
Colon Cancer - Pipeline by Molecular Targeting Technologies Inc, H2 2016
Colon Cancer - Pipeline by MolMed SpA, H2 2016
Colon Cancer - Pipeline by Monopar Therapeutics LLC, H2 2016
Colon Cancer - Pipeline by Multimmune GmbH, H2 2016
Colon Cancer - Pipeline by NormOxys Inc, H2 2016
Colon Cancer - Pipeline by Northwest Biotherapeutics Inc, H2 2016
Colon Cancer - Pipeline by Novartis AG, H2 2016
Colon Cancer - Pipeline by Omeros Corp, H2 2016
Colon Cancer - Pipeline by Omnitura Therapeutics Inc, H2 2016
Colon Cancer - Pipeline by Oncovir Inc, H2 2016
Colon Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016
Colon Cancer - Pipeline by Orega Biotech SAS, H2 2016
Colon Cancer - Pipeline by OSE Immunotherapeutics, H2 2016
Colon Cancer - Pipeline by Panacea Pharmaceuticals Inc, H2 2016
Colon Cancer - Pipeline by Patrys Ltd, H2 2016
Colon Cancer - Pipeline by PharmaCyte Biotech Inc, H2 2016
Colon Cancer - Pipeline by Pharminox Ltd, H2 2016
Colon Cancer - Pipeline by Philogen SpA, H2 2016
Colon Cancer - Pipeline by Pique Therapeutics, H2 2016
Colon Cancer - Pipeline by Plexxikon Inc, H2 2016
Colon Cancer - Pipeline by ProNAi Therapeutics Inc, H2 2016
Colon Cancer - Pipeline by Provecs Medical GmbH, H2 2016
Colon Cancer - Pipeline by Provectus Biopharmaceuticals Inc, H2 2016
Colon Cancer - Pipeline by Qu Biologics Inc, H2 2016
Colon Cancer - Pipeline by Recce Pty Ltd, H2 2016
Colon Cancer - Pipeline by Rexahn Pharmaceuticals Inc, H2 2016
Colon Cancer - Pipeline by Rgenix Inc, H2 2016
Colon Cancer - Pipeline by Sareum Holdings Plc, H2 2016
Colon Cancer - Pipeline by Savoy Pharmaceuticals Inc, H2 2016
Colon Cancer - Pipeline by Sellas Inc, H2 2016
Colon Cancer - Pipeline by Sigma-Tau SpA, H2 2016
Colon Cancer - Pipeline by Sirnaomics Inc, H2 2016
Colon Cancer - Pipeline by SOM Biotech SL, H2 2016
Colon Cancer - Pipeline by Somantix BV, H2 2016
Colon Cancer - Pipeline by Sorrento Therapeutics Inc, H2 2016
Colon Cancer - Pipeline by Sphaera Pharma Pvt Ltd, H2 2016
Colon Cancer - Pipeline by Starpharma Holdings Ltd, H2 2016
Colon Cancer - Pipeline by Sunshine Biopharma Inc, H2 2016
Colon Cancer - Pipeline by Synergys Biotherapeutics Inc, H2 2016
Colon Cancer - Pipeline by TaiRx Inc, H2 2016
Colon Cancer - Pipeline by Taiwan Liposome Company Ltd, H2 2016
Colon Cancer - Pipeline by Takis Srl, H2 2016
Colon Cancer - Pipeline by Targovax ASA, H2 2016
Colon Cancer - Pipeline by Transgene Biotek Ltd, H2 2016
Colon Cancer - Pipeline by TVAX Biomedical Inc, H2 2016
Colon Cancer - Pipeline by Tyg Oncology Ltd, H2 2016
Colon Cancer - Pipeline by TyrNovo Ltd, H2 2016
Colon Cancer - Pipeline by Vaccinogen Inc, H2 2016
Colon Cancer - Pipeline by Vault Pharma Inc, H2 2016
Colon Cancer - Pipeline by Vaxenta Biotechnologies, H2 2016
Colon Cancer - Pipeline by Vaximm AG, H2 2016
Colon Cancer - Pipeline by VG Life Sciences Inc, H2 2016
Colon Cancer - Pipeline by Yakult Honsha Co Ltd, H2 2016
Colon Cancer - Pipeline by Zensun (Shanghai) Sci & Tech Co Ltd, H2 2016
Colon Cancer - Pipeline by ZIOPHARM Oncology Inc, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Colon Cancer - Dormant Projects, H2 2016
Colon Cancer - Dormant Projects (Contd..1), H2 2016
Colon Cancer - Dormant Projects (Contd..2), H2 2016
Colon Cancer - Dormant Projects (Contd..3), H2 2016
Colon Cancer - Dormant Projects (Contd..4), H2 2016
Colon Cancer - Dormant Projects (Contd..5), H2 2016
Colon Cancer - Dormant Projects (Contd..6), H2 2016
Colon Cancer - Dormant Projects (Contd..7), H2 2016
Colon Cancer - Dormant Projects (Contd..8), H2 2016
Colon Cancer - Dormant Projects (Contd..9), H2 2016
Colon Cancer - Dormant Projects (Contd..10), H2 2016
Colon Cancer - Dormant Projects (Contd..11), H2 2016
Colon Cancer - Dormant Projects (Contd..12), H2 2016
Colon Cancer - Dormant Projects (Contd..13), H2 2016
Colon Cancer - Dormant Projects (Contd..14), H2 2016
Colon Cancer - Dormant Projects (Contd..15), H2 2016
Colon Cancer - Dormant Projects (Contd..16), H2 2016
Colon Cancer - Dormant Projects (Contd..17), H2 2016
Colon Cancer - Dormant Projects (Contd..18), H2 2016
Colon Cancer - Dormant Projects (Contd..19), H2 2016
Colon Cancer - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Colon Cancer, H2 2016
Number of Products under Development for Colon Cancer - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Skip to top


Colon Carcinoma - Pipeline Review, H1 2014 US$ 2,000.00 Mar, 2014 · 45 pages
Colorectal Cancer - Pipeline Review, 2015 US$ 4,000.00 Oct, 2015 · 258 pages
Rectal Cancer - Pipeline Review, H2 2016 US$ 2,000.00 Aug, 2016 · 107 pages
Ureter Cancer - Pipeline Review, H2 2016 US$ 2,000.00 Oct, 2016 · 103 pages
Head And Neck Cancer - Pipeline Review, H1 2017 US$ 2,500.00 May, 2017 · 1247 pages

Ask Your Question

Colon Cancer - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: